BioSpace· Nick Paul Taylor·· 4 hours agoPickScore67
Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
In brief
Roche says an exemption clause for mandatory branded-medicine discounts tied to investments in Germany is the country's final opportunity to restore pharma companies' investment confidence, and the proposal must become enforceable law by early next year. Germany's reform plan raises the mandatory manufacturer discount on branded medicines from 7% to 15.5% starting Jan. 1, 2027, and a clause proposed by a government committee late last month would grant reductions to companies meeting investment criteria in Germany.
Why it matters
Germany's mandatory branded-drug discount would rise from 7% to 15.5%, and the investment-linked exemption offers a direct gauge of the reform's impact on pharma investment.
Source: BioSpace · biospace.com